Boston Biotech Clinical Research
  • Home
    • SCIO Path to Approval
  • Early Clinical Research
    • Strategy and TPP
    • Translational Medicine and Epigenetics
    • Biologics, Cell and Gene Therapy
    • Real World Evidence
    • Repurposing
  • Orphan Drug Solutions
    • Biomarkers and Surrogate Endpoints
    • Regulatory Affairs FDA and EMA
    • Medical Affairs and Clinical Research
    • Due Diligence
    • Trial Management & Trial Rescue
  • People
    • Senior Advisors
      • Candida Fratazzi
      • Claudio Carini
      • Federico Goodsaid
    • Our Clients
    • Our Collaborators
    • Testimonials
  • Resources
    • BBCR Voice
    • Case Studies
    • Published Studies
    • Conferences & Presentations
    • Job Opportunities
    • Contact Info
Select Page

Real World Evidence

BBCR Company News

Gene Therapy for Rare Disorders Europe 2019 – October 15th – 17th, London

July 15th, 2019 | Real World Evidence

BBCR is Hiring! Boston Biotech Clinical Research is looking for a Full Time Associate Clinical Scientist to join our team!

June 21st, 2019 | Real World Evidence

SCIO Helps Early Stage Biotech Company Evaluation

January 24th, 2019 | Real World Evidence

A success story by BBCR Consulting: Candida Fratazzi MD was CMO at Ichorion Therapeutics in 2018

December 17th, 2018 | Real World Evidence

Welcome to BBCR’s New Website!

December 7th, 2018 | Real World Evidence
Newer posts »

Categories

  • Biomarkers & Surrogate Endpoints
  • Company News
  • Drug Development
  • Due Diligence
  • Early Clinical Development
  • Industry News
  • Medical Affairs and Clinical Research
  • Miscellaneous
  • Orphan Diseases
  • Pre-IND
  • Precision Medicine
  • Rare Disease
  • Real World Evidence
  • Regulatory
  • Regulatory Affairs
  • Strategy and TPP
  • Translation Medicine and Epigenetics
  • Trial Management
  • Trial Rescue

Recent Posts

  • Who is BBCR and how do we help pharmaceutical innovators in the specialized rare diseases and orphan drug industries? We invite you to learn more at bbcrconsulting.com.
  • Accelerate Drug Development with Biomarker Strategy in Orphan Diseases and Precision Medicine
  • At BBCR, our team of seasoned experts is dedicated to helping clients navigate the intricate landscape of rare genetic conditions and unsolved diseases. We work hand in hand with product developers to create the most effective strategies for bringing innovative treatments to market.
  • Our experienced CRO Management and Drug development team identify study remediation strategies and provide a resource for any Study Rescue. We invite you to reach out to learn more – visit bbcrconsulting.com.
  • A pioneering figure in the area of rare diseases and orphan drug early-stage clinical research and regulatory strategies, Dr. Candida Fratazzi has an impressive 25-year track record in this specialized field.

RSS Nasdaq Globe Newswire

  • Immuneering Announces Closing of $25 Million Private Placement August 26, 2025
  • Evoke Pharma and EVERSANA Expand GIMOTI® Access to Gastro Health and Other Large GI Practices through Omnicell Relationship August 26, 2025
  • [Latest] Global Chemical Reagents Market Size/Share Worth USD 26.5 Billion by 2034 at a 7.5 CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) August 25, 2025
  • IMDX CFO Andrea James Featured in Empowered Patient Podcast on Democratizing Molecular Diagnostics August 25, 2025
PRIVACY POLICY
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn

©2025 Boston Biotech Clinical Research. All Rights Reserved.   |   Web Design by Nisse Designs